Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Iván Alvarez-Twose 1, 5 , Almudena Matito 1, 5 , José Mário Morgado 1, 5 , Laura Sánchez-Muñoz 1, 5 , María Jara-Acevedo 2, 5 , Andrés García-Montero 2, 5 , Andrea Mayado 2, 5 , Carolina Caldas 2, 5 , Cristina Teodósio 3 , Javier Ignacio Muñoz-González 2, 5 , Manuela Mollejo 4, 5 , Luis Escribano 2, 5 and Alberto Orfao 2, 5 1 Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain 2 Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain 3 Department of Immunology, Erasmus Medical Center, University of Rotterdam, Rotterdam, The Netherlands 4 Department of Pathology, Hospital Virgen de la Salud, Toledo, Spain 5 Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain Correspondence to: Iván Alvarez-Twose, email: ivana@sescam.jccm.es Keywords: mast cell, mastocytosis, well-differentiated systemic mastocytosis, imatinib, KIT Received: March 01, 2016 Accepted: May 29, 2016 Published: July 19, 2016 ABSTRACT Resistance to imatinib has been recurrently reported in systemic mastocytosis (SM) carrying exon 17 KIT mutations. We evaluated the efficacy and safety of imatinib therapy in 10 adult SM patients lacking exon 17 KIT mutations, 9 of which fulfilled criteria for well-differentiated SM (WDSM). The World Health Organization 2008 disease categories among WDSM patients were mast cell (MC) leukemia ( n = 3), indolent SM ( n = 3) and cutaneous mastocytosis ( n = 3); the remainder case had SM associated with a clonal haematological non-MC disease. Patients were given imatinib for 12 months –400 or 300 mg daily depending on the presence vs. absence of > 30% bone marrow (BM) MCs and/or signs of advanced disease–. Absence of exon 17 KIT mutations was confirmed in highly-purified BM MCs by peptide nucleic acid-mediated PCR, while mutations involving other exons were investigated by direct sequencing of purified BM MC DNA. Complete response (CR) was defined as resolution of BM MC infiltration, skin lesions, organomegalies and MC-mediator release-associated symptoms, plus normalization of serum tryptase. Criteria for partial response (PR) included ≥ 50% reduction in BM MC infiltration and improvement of skin lesions and/or organomegalies. Treatment was well-tolerated with an overall response rate of 50%, including early and sustained CR in four patients, three of whom had extracellular mutations of KIT , and PR in one case. This later patient and all non-responders ( n = 5) showed wild-type KIT . These results together with previous data from the literature support the relevance of the KIT mutational status in selecting SM patients who are candidates for imatinib therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase
Sanger, F., & Coulson, A. R. (1975) · Journal of Molecular Biology · doi:10.1016/0022-2836(75)90213-2 · Cited by 2,709 · cited 2×
“Mutations involving other exons of KIT were also investigated by direct sequencing of PCR products using the Sanger method [23], such mutations being detected in 4/10 cases.”
BackgroundMethodValent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 1×
“Such variability is due, at least in part, to the lack of consensus treatment response criteria for mastocytosis until 2007, when a first proposal was formulated [40].”
BackgroundSelf-citationJara-Acevedo, M., Teodosio, C., Sanchez-Muñoz, L., Álvarez-Twose, I., Mayado, A., Caldas, C., Matito, A., Morgado, J. M., Muñoz-González, J. I., Escribano, L., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.72 · Cited by 114 · cited 2×
“Due to the rarity of these SM cases lacking exon 17 KIT mutations (≤ 4%) [6], a critical review of mastocytosis cases treated with imatinib who have been reported in the literature is also provided to better estimate the response rates to imatinib according to the KIT mutational status.”
BackgroundSelf-citationÁlvarez-Twose, I., Jara-Acevedo, M., Morgado, J. M., García-Montero, A., Sánchez-Muñoz, L., Teodósio, C., Matito, A., Mayado, A., Caldas, C., Mollejo, M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.05.008 · Cited by 102
Self-citation
Cited by
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000646 · Cited by 317
Valent, P., Hartmann, K., Schwaab, J., Alvarez-Twose, I., Brockow, K., Bonadonna, P., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.007 · Cited by 72
Review and updates on systemic mastocytosis and related entities
Li, J. Y., Ryder, C. B., Zhang, H., Cockey, S. G., Hyjek, E., Moscinski, L. C., Sagatys, E., & Song, J. (2023) · Cancers · doi:10.3390/cancers15235626 · Cited by 31
“Germline KIT mutations have been found to be associated with familial mastocytosis [57,58].”
BackgroundInfluentialMastocytosis and related entities: A practical roadmap
Beyens, M., Elst, J., van der Poorten, M.-L., Van Gasse, A., Toscano, A., Verlinden, A., Vermeulen, K., Maes, M.-B., Oude Elberink, J. N. G. H., Ebo, D., et al. (2023) · Acta Clinica Belgica · doi:10.1080/17843286.2022.2137631 · Cited by 13
Metadata
- Authors
- Alvarez-Twose, I., Matito, A., Morgado, J. M., Sánchez-Muñoz, L., Jara-Acevedo, M., García-Montero, A., Mayado, A., Caldas, C., Teodósio, C., Muñoz-González, J. I., Mollejo, M., Escribano, L., & Orfao, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-07-19
- Volume
- 8
- Issue
- 40
- Pages
- 68950-68963
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2485655499
- Cited by
- 102
- References
- 5
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. https://app.cochat.ai/papers/10.18632/oncotarget.10711
- The paper
- Alvarez-Twose, I., Matito, A., Morgado, J. M., Sánchez-Muñoz, L., Jara-Acevedo, M., García-Montero, A., Mayado, A., Caldas, C., Teodósio, C., Muñoz-González, J. I., Mollejo, M., Escribano, L., & Orfao, A. (2017). Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. https://doi.org/10.18632/oncotarget.10711
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.